3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
5
Active not recruiting
5
Recruiting
3
Completed
2
Withdrawn
1
Unknown
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Carcinoma, Non-Small-Cell Lung
31
Melanoma
20
Neoplasms
13
Breast Neoplasms
11
Stomach Neoplasms
9
Pancreatic Neoplasms
9
Neoplasm Metastasis
9
Lung Neoplasms
9
Head and Neck Neoplasms
9
Triple Negative Breast Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
8
Ovarian Neoplasms
8
Colorectal Neoplasms
7
Carcinoma, Renal Cell
7
Carcinoma, Hepatocellular
6
Prostatic Neoplasms
4
Hodgkin Disease
4
Glioblastoma
4
Carcinoma, Transitional Cell
4
Carcinoma
4
Uterine Cervical Neoplasms
3
Liver Neoplasms
3
Kidney Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Esophageal Neoplasms
3
Adenocarcinoma
3
Small Cell Lung Carcinoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neoplasms, Squamous Cell
2
Mesothelioma
2
Interventions
Cisplatin
4
tremelimumab
3
Pemetrexed
3
durvalumab
2
atezolizumab
2
Radiotherapy
2
Nivolumab
2
Mitomycin
2
Doxorubicin
2
toripalimab
1
talazoparib
1
rucaparib
1
regorafenib
1
ranpirnase
1
pembrolizumab
1
niraparib
1
liposomal doxorubicin
1
dostarlimab
1
cemiplimab
1
bemcentinib
1
avelumab
1
abemaciclib
1
Vinorelbine
1
Vinblastine
1
Thiostrepton
1
Surgical Procedures, Operative
1
Oxaliplatin
1
One-Lung Ventilation
1
Neoadjuvant Therapy
1
Megestrol Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Mesothelioma, Malignant
×
pembrolizumab
×
Clear all
NCT03654833
2023-03-14
MiST
University of Leicester
Phase 2
Unknown
186 enrolled